Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa
Journal of Thrombosis and Haemostasis · 2023
DOI: 10.1016/j.jtha.2023.09.009 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023. Verfasst von Justine H Ryu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; Division of Hemat…. Hauptthemen laut MEDLINE: von Willebrand Disease, Type 2, Hemostatics, Hemophilia A, von Willebrand Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Novo Nordisk, Genentech.
Abstract (Originalsprache)
Type 2 Normandy von Willebrand disease (type 2N VWD) is a rare qualitative defect in von Willebrand factor (VWF) that results in impaired factor VIII (FVIII) binding and consequently reduced FVIII levels. Current perioperative strategies require VWF concentrates to attain durable hemostatic FVIII levels. This case highlights the successful perioperative management of a 78-year-old female with type 2N VWD and coronary artery disease utilizing efanesoctocog alfa, a novel long-acting recombinant FVIII product approved for hemophilia A. By decoupling the FVIII-VWF interaction, efanesoctocog alfa achieves prolonged FVIII circulation independent of VWF. A single administration targeting 90% FVIII levels yielded sustained FVIII elevation without achieving supraphysiologic VWF levels, thus mitigating potential cardiovascular risks. This is the first report of efanesoctocog alfa use in type 2N VWD. Further clinical studies are necessary to corroborate its efficacy and safety for this indication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; Division of Hematology and Hematologic Malignancies, Beth Israel Deaconess Medical Cent…
Förderung
- Novo Nordisk
- Genentech
Zitieren
APA
Ryu, J. H., Bauer, K. A., & Schulman, S. (2023). Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2023.09.009
Vancouver
Ryu JH, Bauer KA, Schulman S. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa. Journal of Thrombosis and Haemostasis. 2023. doi:10.1016/j.jtha.2023.09.009
BibTeX
@article{Ryu2023,
author = {Ryu, Justine H and Bauer, Kenneth A and Schulman, Sol},
title = {Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa},
journal = {Journal of Thrombosis and Haemostasis},
year = {2023},
doi = {10.1016/j.jtha.2023.09.009}
}
EUVIMED